Today: 3 July 2026
Opendoor stock: holiday pause puts focus on short interest math
3 July 2026
3 mins read

Opendoor stock: holiday pause puts focus on short interest math

NEW YORK, July 3, 2026, 06:03 EDT

  • U.S. stock markets are shut Friday for the Independence Day holiday. On regular days, Nasdaq trading hours run 9:30 a.m. to 4:00 p.m. Eastern.
  • Opendoor Technologies finished at $4.90 on July 2, slipping 0.81%. Volume hit 90.05 million shares.
  • Trading volume for the session was about 11.2% of Opendoor’s public float and made up 58.6% of its reported short interest, according to MarketWatch float and short interest data.
  • The next signal in housing is mortgage rates. Freddie Mac’s 30-year fixed dropped to 6.43% as of July 2. FRED updates again on July 9.

U.S. markets are closed Friday. Opendoor traders have a three-day break after a high-volume reversal session that broke the usual pre-holiday fade pattern.

The stock finished July 2 at $4.90, off 0.81%. Shares moved between $4.75 and $5.17 during the session. In after-hours, it dipped to $4.87 with about 599,260 shares changing hands, according to MarketWatch data. Regular trading saw volume hit 90.05 million, or 214% of the 65-day average.

That’s the clearer investor story. Opendoor wasn’t just active. Its single-day turnover put a dent in the stock’s short base. MarketWatch shows public float at 806.03 million shares, with short interest at 153.72 million shares as of June 15, or 19.07% of float. Volume on Thursday was 58.6% of those shorted shares.

Opendoor trading measureLatest figureWhat it says
Regular close$4.90Fell 0.81% on July 2
Regular volume90.05 mln shares2.14 times the 65-day average
Public float806.03 mln sharesThursday’s turnover was 11.2% of the float
Short interest153.72 mln sharesThursday’s trading hit 58.6% of shares sold short
Five-day performance+12.13%Shares gained for the week, even with the holiday

The Nasdaq Composite dropped 0.8% Thursday. The S&P 500 was about flat, and the Dow added 1.1%, AP market data showed. Week to date, the Nasdaq is up 2.1%, the S&P 500 rose 1.8% and the Dow is up 2%. Opendoor jumped 12.13% over five days, outpacing the indexes despite Thursday’s pullback.

AssetLast closeLatest moveWeek through Thursday
Opendoor Technologies Inc. $4.90down 0.81%up 12.13% over the last five days
Nasdaq Composite25,832.67fell 0.8%gained 2.1% this week
S&P 5007,483.24edged higher, less than 0.1%added 1.8% for the week
Russell 20002,996.11lost 0.5%dropped 0.5% since last Friday

The stock picked up a second push from forced buying. Opendoor on May 27 said it will join the Russell 3000 Index after the U.S. market closes June 26. That timing muddies this month’s volume as a read on pure housing sentiment. Index flows, retail trades and short covering could all be showing up at once.

Opendoor’s latest numbers stayed uneven. Revenue fell to $720 million from $1.15 billion in the first quarter last year, and net loss widened to $173 million from $85 million. The company bought 2,474 homes, fewer than 3,609 a year ago but more than 1,706 last quarter.

Opendoor is betting on faster turnarounds and better margins. The company said its older homes, or aged inventory, made up just 10% of its stock at the end of Q1, down from 51% at the end of Q3 2025. For the second quarter, the company expects revenue to rise about 25% from Q1 and projects adjusted EBITDA close to breakeven—give or take a few million dollars.

Opendoor CEO Kaz Nejatian said in the May update that “the October cohort was just the start,” with acquisition contracts up 2x from the previous quarter. “Better acquisitions, faster turns, stronger margins. The machine is working,” Nejatian said. Opendoor Technologies Inc.

Finance chief Christy Schwartz told the earnings call that Opendoor expects to reach adjusted EBITDA profitability “on a 12-month go-forward basis” starting in the second quarter. Schwartz said Q1 included over 5,000 acquisition contracts, the most since Q2 2022. The Motley Fool

Wall Street is divided. Six analysts have weighed in on the stock in the last three months, according to Google Finance. Two say buy, three have it at hold, one says sell. Price targets for the next year are all over the map, from $2.25 up to $8.00, averaging $5.75. The lowest target is 54% under the last close at $4.90, while the highest is 63% above.

AnalystFirmRatingTarget
Matthew CostMorgan StanleyHold$5.50
Ryan TomaselloKBWSell$2.25
Gaurav MehtaAlliance Global PartnersBuy$8.00
Stephen JuUBSHold$5.00
Dae LeeJ.P. MorganBuy$8.00

The week opens with U.S. stock markets closed Friday and slated to reopen on Monday, unless there’s a last-minute holiday change. Opendoor’s focus is shifting to whether volume holds up now that Russell reconstitution flows are done, not just the next market close.

Mortgage rates come up next on the macro calendar. Freddie Mac put the 30-year fixed at 6.43% as of July 2, a slip from 6.49% the prior week and down from 6.67% last year. FRED names July 9 as the next release.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation.

Stock Market Today

  • Novo Nordisk Drops as Medicare Caps Wegovy Costs in U.S.
    July 3, 2026, 6:31 AM EDT. Novo Nordisk shares fell 1.36% to DKK 327.50, lagging the OMX Copenhagen 25, after Medicare set a new $245 net price for Wegovy under the CMS GLP-1 Bridge program. The move fixes patient copays at $50 and aims to widen obesity coverage, cutting prices for the U.S. market. Analysts now expect only modest sales growth, with Novo's adjusted obesity-care sales up 22% but U.S. sales down 11% due to the lower pricing. Wegovy pill prescriptions hit 3 million since January. The Bridge program, which extends to 2027 and covers rivals such as Eli Lilly, puts more pressure on Novo's U.S. pricing.
Novo Nordisk (CPH:NOVO-B) edges lower as Wegovy gains checked by Medicare limits
Previous Story

Novo Nordisk (CPH:NOVO-B) edges lower as Wegovy gains checked by Medicare limits

SoFi stock small-business lending gains lose momentum ahead of July 4 break
Next Story

SoFi stock small-business lending gains lose momentum ahead of July 4 break

Go toTop